Trial Profile
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, For Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TiP ENCORE
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 09 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 29 Feb 2024.
- 24 Feb 2023 Planned End Date changed from 1 May 2023 to 1 Mar 2024.
- 24 Feb 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2023.